The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...

The three biggest pharmacy benefit managers made more than $7.3 billion over five years marking up the prices of specialty ...

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Mattingly is an associate professor and vice chair of research in the Department of Pharmacotherapy at the University of Utah ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...

The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...

The pharmaceutical supply chain is a sector infamous for glacially slow adjustments, lackluster reform, lack of transparency ...

Pharmacy benefit managers, which serve as the middlemen between drug makers, insurers and pharmacies, reaped $7.3 billion in ...

Says that while the company offers customers 100% pass-through options, “a small number have historically elected other models.” Witty says “We ...

The new document focuses on the influence of PBMs over the market for specialty generic drugs for illnesses like cancer, ...

"While this information is theoretically available to the public, institutional owners' holdings are challenging to identify ...